STStefan Teipel

Stefan Teipel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefan Teipel has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protocol of a dyadic, app-supported collaborative care intervention trial for informal caregivers of people living with dementia—the multi-center living@home study

    by Eva Gläser, Fabian Kleinke, Milena Armanowski, Maresa Buchholz, Andreas Fellgiebel, Marius Gerdes, Wolfgang Hoffmann, Bernhard Holle, Ingo Kilimann, Kerstin Köhler, et al.

    Background: Informal caregivers provide a large part of the care required by people living with dementia. With disease progression, the burden on caregivers typically increases. Dyadic interventions, addressing both the caregiver and the person living with dementia simultaneously, can help to stabilize home care settings. This study examines the effectiveness and cost-effectiveness of an app-assisted dementia care intervention. Methods: Living@home is a two-arm, randomized, controlled, multi-center interventional study designed to evaluate the effectiveness of a dyadic, app-based intervention on home care stability as well as the cost-effectiveness of this approach. The inclusion criteria are a formal diagnosis of dementia and living in their own home for the person with dementia, as well as access to a smartphone and internet for the informal caregiver. A total of 554 dyads will be recruited in five participating memory clinics and randomized (1:1 ratio, using block randomization) into either the intervention or the control group. The intervention group will receive personalized dementia care management for a period of 12 months. A mobile health app connecting caregivers with a Family Care Specialist offers informal caregivers access to memory clinics and Care Specialists at any time, monitoring of their health situation through real-time data collection, overview of care-related tasks, information and alerts tailored to the reported individual caregiver burden. The control group receives care-as-usual. Both groups will be assessed at baseline and after 12 months. The primary outcome is the caregiver’s perseverance time (Perseverance Time Scale), and crucial secondary supportive outcomes are neuropsychiatric symptoms in the person living with dementia (Neuropsychiatric Inventory), and the caregiver’s perceived burden (Zarit Burden Interview). Further secondary outcomes include the caregiver’s resilience and self-efficacy, the dyads’ physiological stress level (as measured by hair cortisol concentrations), health-related quality of life, caregiver depression and anxiety, dyads’ unmet needs, and cost-effectiveness. Intervention effects will be estimated by using multivariate regression analyses. Discussion: Evidence on the effectiveness and cost-effectiveness of the intervention created from this study can help to inform decision makers and support the transition of the intervention to standard care. Trial registration: ClinicalTrials.gov NCT07251088, Registered 25.11.2025

  • Open Access

    Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer’s disease spectrum

    by Stefan Teipel, Alice Grazia, Oliver Peters, Josef Priller, Anja Schneider, Jens Wiltfang, Claudia Bartels, Björn Hendrik Schott, Frank Jessen, Emrah Duezel, et al.

    Background: Anticholinergic side effects of pharmacological treatment are a risk factor for cognitive decline in older people. Here, we aimed to assess the effect of anticholinergic burden of treatment on longitudinal rates of cognitive change and atrophy in functionally related brain regions in people from the Alzheimer’s disease (AD) spectrum. Methods: We determined associations of anticholinergic burden of pharmacological treatment with rates of global cognition, episodic memory and executive function decline as well as basal forebrain and hippocampus atrophy in participants of the memory clinic based DELCODE cohort, spanning the range from cognitively normal through subjective cognitive decline, mild cognitive impairment and AD dementia. We had 794 cases with neuropsychological outcomes, and a subset of 703 cases with MRI outcomes. Effects were assessed using mixed effect models in a Bayesian framework using prior-insensitive cross-validated Bayes factors (CV-BF) and parameter estimates. Results: We found moderate evidence for an association of anticholinergic burden with baseline levels of cognitive impairment for the PACC5 as a global cognitive function score (CV-BF = 9.0) with more impairments with higher burden, but not with basal forebrain and hippocampus volumes, and weak evidence for an association of anticholinergic burden with longitudinal rates of change in the trail-making test B as an executive function score (CV-BF = 2.5), but not for other cognitive scores and not for brain volumes. Conclusion: In the presence of prodromal or manifest AD, in a memory clinic-based cohort anticholinergic burden had only a modest effect on cognitive decline and no effect on atrophy in brain regions that are related to the cholinergic system.

  • Demenzdiagnose mittels Biomarker – geht das?

    by Stefan Teipel

    Article published online: 17 March 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    What influences life expectancy in people with dementia? Social support as an emerging protective factor

    by Iris Blotenberg, Melanie Boekholt, Bernhard Michalowsky, Moritz Platen, Francisca S Rodriguez, Stefan Teipel, Wolfgang Hoffmann, Jochen René Thyrian

    Background: The aim of this study was to investigate the role of support from the social environment for the life expectancy in people with dementia beyond well-established individual demographic and clinical predictors over a period of up to 8 years. Methods: The analyses are based on data from 500 community-dwelling individuals in Germany who tested positive for dementia and were followed up for up to 8 years. Life expectancy was examined in relation to perceived social support as well as well-established socio-demographic (age, sex) and clinical predictors (cognitive status, functional status, comorbidities), using Cox regressions. Results: Greater support from the social environment reduced the risk of mortality (hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.63–0.98), with the role of emotional support being particularly important. Furthermore, higher age was associated with an increased mortality risk (HR: 1.08; 95% CI: 1.05–1.11), while female sex (HR: 0.64; 95% CI: 0.48–0.85) and higher cognitive (HR: 0.96; 95% CI: 0.93–0.98) and functional status (HR: 0.91; 95% CI: 0.86–0.97) were associated with higher life expectancy. Conclusion: Our study provides novel evidence that less support from the social environment, especially emotional support, is a risk factor for shorter life expectancy in people with dementia—beyond known clinical factors. Not only the clinical and caregiving needs but also their psychosocial needs of individuals with dementia should be emphasised.


  • Open Access

    Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)

    by Frank Jessen, Annika Spottke, Henning Boecker, Frederic Brosseron, Katharina Buerger, Cihan Catak, Klaus Fliessbach, Christiana Franke, Manuel Fuentes, Michael T. Heneka, et al.

    Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer’s disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention. The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics. In addition, individuals with amnestic MCI, mild Alzheimer’s dementia patients, first-degree relatives of patients with Alzheimer’s dementia, and cognitively unimpaired control subjects are studied. The total number of subjects to be enrolled is 1000. Participants receive extensive clinical and neuropsychological assessments, magnetic resonance imaging, positron emission tomography, and biomaterial collection is perfomed. In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets. In comparison with the control group, patients with SCD showed slightly poorer performance on cognitive and functional measures (Alzheimer’s Disease Assessment Scale—cognitive part, Clinical Dementia Rating, Functional Activities Questionnaire), with all mean scores in a range which would be considered unimpaired. APOE4 genotype was enriched in the SCD group in comparison to what would be expected in the population and the frequency was significantly higher in comparison to the control group. CSF Aβ42 was lower in the SCD group in comparison to the control group at a statistical trend with age as a covariate. There were no group differences in Tau or pTau concentrations between the SCD and the control groups. The differences in all measures between the MCI group and the AD group were as expected. The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late-stage preclinical AD. This is indicated by slightly lower performance in a range of measures in SCD in comparison to the control subjects as well as by enriched APOE4 frequency and lower CSF Aβ42 concentration. German Clinical Trials Register DRKS00007966 . Registered 4 May 2015.


  • Detecting the Effect of Alzheimer’s Disease on Everyday Motion Behavior

    by Thomas Kirste, Philipp Koldrack, Susanne Schubert, Stefan Teipel


  • Open Access

    Medication management for people with dementia in primary care: description of implementation in the DelpHi study

    by Thomas Fiß, Jochen René Thyrian, Diana Wucherer, Grit Aßmann, Ingo Kilimann, Stefan J Teipel, Wolfgang Hoffmann

    Background: As the population ages, the relative and absolute number of age-associated diseases such as dementia will increase. Evaluation of the suitability and intake of medication and pharmacological treatment is an important aspect of care for people with dementia, especially if they live at home. Regular medication reviews and systematic cooperation between physicians and pharmacists are not common in routine care. Medication management (MM), based on such a comprehensive home medication review could help to reduce drug-related problems and costs. The present article presents a medication management specifically for the application in the ambulatory setting and describes its implementation as part of a larger trial. Methods/design: A home medication review (HMR) and MM is implemented as part of the DelpHi study, a population based prospective, cluster-randomized controlled intervention study to test the efficacy and efficiency of the implementation of a collaborative care model in primary care. Participants: people with dementia (PWD) and their caregivers are recruited by the patient’s general practitioner. Inclusion criteria are a positive screening result for dementia, living at home and regular intake of drugs. PWD are asked to specify their regular pharmacy which is asked to participate in the study, too. Intervention: a comprehensive HMR is conducted as computer-assisted personal interview by specifically qualified Dementia Care Manager (DCM) at the people’s home. It includes detailed information about drugs taken, their storage, administration, adherence and adverse events. The MM is conducted in cooperation between DCM, pharmacist and general practitioner and consists of a pharmaceutical evaluation, pharmaceutical recommendations and their application. Pharmacists are trained and provided with regularly updated information. The MM is designed to give information and recommendations concerning antidementia drugs, occurrence of drug related problems, intake of anticholinergic drugs, potentially clinically relevant drug-drug-interactions, adverse drug events and medication adherence. Discussion: The DelpHi-approach for medication management employs comprehensive instruments and procedures in the primary care setting under routine care conditions, and this approach should be useful in improving pharmacotherapy as part of the comprehensive treatment and care for people with dementia. Trial registration: The trial is registered at ClinicalTrials.gov, number NCT01401582.


  • Open Access

    Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial

    by Jochen René Thyrian, Thomas Fiß, Adina Dreier, Georgia Böwing, Aniela Angelow, Sven Lueke, Stefan Teipel, Steffen Fleßa, Hans Jörgen Grabe, Harald Jürgen Freyberger, et al.

    The provision of appropriate medical and nursing care for people with dementia is a major challenge for the healthcare system in Germany. New models of healthcare provision need to be developed, tested and implemented on the population level. Trials in which collaborative care for dementia in the primary care setting were studied have demonstrated its effectiveness. These studies have been conducted in different healthcare systems, however, so it is unclear whether these results extend to the specific context of the German healthcare system.